Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Trevi Therapeutics Q3 2026 Results: Net Loss of $21.5M, Loss Widens

Trevi Therapeutics reported a net loss of $52.4 million for the nine months ended September 30, 2026, compared to $34.4 million in the prior year, primarily driven by increased R&D expenses for its Haduvio clinical trials. The company significantly strengthened its balance sheet through a common stock offering, ending the period with $299.4 million in cash, cash equivalents, and marketable securities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-21.5-11.8
Net income-21.5-11.8
EPS (diluted, $ a share)$-0.13$-0.08

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: TRVI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Trevi Therapeutics, Inc.: key numbers

Share price
$13.29Close, Nov 16
Market cap
$1.89B
Shares outstanding
142.56MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Trevi Therapeutics, Inc.

All →
4:27 PM ET 8-K
Financial Results

Trevi Therapeutics Financial Results

Trevi Therapeutics reported financial results for the third quarter of 2026, highlighting the initiation of its Phase 3 OCEAN-2 trial for IPF-related chronic cough. The company also reached alignment with the FDA on a Phase 2 development path for non-IPF ILD-related chronic cough, with a trial expected to start in Q1 2027. Trevi maintains a cash runway into 2030 to fund its key clinical milestones.

Term
Q3 2026

“This is an important time of clinical execution for Trevi as we actively open sites globally and enroll patients across all three active trials. We also recently aligned with the FDA on our non-IPF ILD-related chronic cough program and expect to initiate a Phase 2 dose-ranging trial in the first quarter of 2027.”

Jennifer Good, President and CEO of Trevi Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.